ADC Therapeutics SA
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
Switzerland
Business Address
BIOPOLE, EPALINGES, V8, 1066
Mailing Address
BIOPOLE, EPALINGES, V8, 1066
Phone
41 21 653 02 00
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | March 10, 2026 | View on SEC |
| 10-K Annual financial report | March 10, 2026 | View on SEC |
| 8-K Current report of material events | March 10, 2026 | View on SEC |
| 8-K Current report of material events | February 23, 2026 | View on SEC |
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
Annual Reports
10-K
March 10, 2026
- ZYNLONTA's continued commercial growth, with 2025 revenue reaching $125.7 million and 2026 guidance of $130-$150 million.
- Advancement of Camidanalamab Tesirine (Cami) into Phase 3 clinical trials for peripheral T-cell lymphoma (PTCL).
Insider Trading
STRONG SELL
1 insiders
6 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.